Recursion Pharmaceuticals (RXRX) News Today

Recursion Pharmaceuticals, Inc. (RXRX) — Shares traded down today after Q1 results that mixed an EPS beat and strong clinical updates with a sharp year‑over‑year revenue decline. Investors are parsing encouraging program milestones and a buy rating/price target from Needham against lower collaboration revenue and guidance uncertainty.

• Positive Sentiment: Management highlighted tangible clinical progress across wholly‑owned and partnered programs (REC‑1245, REC‑4881, REC‑4539), including early REC‑1245 safety/PK data and FDA engagement on REC‑4881 — items that support long‑term value creation. Press Release
• Positive Sentiment: Early clinical data for RBM39 degrader REC‑1245 were described as well‑tolerated with dose‑dependent PK and no DLTs to date — an encouraging Phase 1/2 signal that analysts and biotech investors typically reward. Yahoo AI Stock Article
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set an $8 price target, implying substantial upside from current levels and providing a catalyst if broader sentiment improves. Benzinga
• Neutral Sentiment: Q1 results and the earnings/strategy call emphasized “signal over noise” and prioritizing proof‑points from AI‑driven programs — a message that supports thesis execution but is not an immediate financial catalyst. Earnings Transcript
• Neutral Sentiment: Insider transaction: Director Blake Borgeson sold 30,000 shares under a pre‑arranged Rule 10b5‑1 plan (small ~0.48% reduction in his holdings), a routine disclosure that appears procedural rather than a red flag. Insider Trades
• Negative Sentiment: Revenue missed expectations materially — Q1 revenue of $6.47M versus ~$15.8M expected, down ~57% year‑over‑year as Roche collaboration income declined; this top‑line deterioration is the primary near‑term driver of the share pullback. MarketBeat Earnings
• Negative Sentiment: Despite an EPS beat (loss of $0.22 vs. consensus ‑$0.30), the company still shows negative margins and returns, and analysts expect continued losses — meaning valuation depends heavily on future trial readouts and partnership revenue recovery. Zacks